{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "byline": {"original": "By DAVID GELLES", "person": [{"rank": 1, "role": "reported", "firstname": "David", "organization": "", "lastname": "GELLES"}]}, "abstract": "Valeant, which failed in its attempt to acquire the Botox maker Allergan last year, is now in talks with Salix, according to a person briefed on the matter. The British drug maker Shire, too, is interested.", "type_of_material": "Blog", "word_count": "381", "lead_paragraph": null, "pub_date": "2015-02-13T12:35:47Z", "document_type": "blogpost", "slideshow_credits": null, "headline": {"main": "Drug Maker Salix Is Once Again a Potential Takeover Target", "kicker": "DealBook"}, "snippet": "Valeant, which failed in its attempt to acquire the Botox maker Allergan last year, is now in talks with Salix, according to a person briefed on the matter. The British drug maker Shire, too, is interested.", "multimedia": [], "web_url": "http://dealbook.nytimes.com/2015/02/13/drug-maker-salix-is-once-again-a-potential-takeover-target/", "keywords": [{"rank": "1", "value": "Salix Pharmaceuticals Ltd", "name": "organizations"}, {"rank": "2", "value": "Shire PLC", "name": "organizations"}, {"rank": "3", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "1", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "blog": [], "_id": "54de366238f0d841787c9638", "source": "The New York Times"}